65,437 trials
Breast Cancer
Primary: Progression Free Survival Using the RECIST 1.1 Criteria — 9.33; 11.30 months
Breast Cancer
Primary: Percentage of Participants With a Pathologic Complete Response — 48.0; 40.5 percentage of participants — p=0.0508
Gingival Recession, Generalized
Primary: Percentage of Defect Coverage — 79.47; 85.97 percentage of root coverage
Dry Eye Syndrome
Primary: Change From Baseline in Frequency of Dry Eye Symptoms (SANDE) — -8.0; -10.0; -15.0; -23.4 Frequency of symptoms per day
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Cervical Cancer · Acquired Immunodeficiency Syndrome
Primary: Treatment Completion Rate — 37 Participants
Primary Open-angle Glaucoma (POAG) · Ocular Hypertension
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) — 2; 0; 2; 0 Participants
Cerebral Palsy · Exercise Therapy · Postural Balance
Primary: Segmental Assessment on Trunk Control-static — 8; 8 score on a scale — p=< 0.05
Type 2 Diabetes
Primary: Myocardial Glucose Uptake — 0.055; 0.0399; 0.0373 umol/g/min — p=0.65
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q)
Primary: Percentage of Patients Who Are Able to Receive at Least One DLI Treatment — 36 Participants
Obesity · Neoplasms
Primary: Area Under the Curve (AUC) on Cycle 1 Day 1 and Cycle 1 Day 9 — 6.84; 8.28 AUC (ug/ml)*h — p=0.4882
Cancer · Leukemia · Lymphoma
Primary: Response Rate — 0; 0; 0 participants
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Meningococcal Infection
Primary: Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Against Neisseria Meningitidis Serogroups Antibody Titers Greater Than or Equal to (≥)…
Sickle Cell Disease
Primary: Fetal Hemoglobin Level — 8.3 Percentage